$MTEM
Molecular Templates, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020038063 Filed on August 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $6.910M $5.447M $7.010M
YoY Change 26.86% 298.46% 1354.36%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.410M $4.610M $4.940M
YoY Change 39.05% 23.92% 69.76%
% of Gross Profit
Research & Development $30.41M $10.24M $8.454M
YoY Change 196.92% 33.69% 26.37%
% of Gross Profit
Depreciation & Amortization $800.0K $500.0K $177.0K
YoY Change 60.0% 316.67% 145.83%
% of Gross Profit
Operating Expenses $36.83M $14.85M $8.454M
YoY Change 148.02% 30.47% -11.91%
Operating Profit -$29.92M -$9.401M
YoY Change 218.23% -6.11%
Interest Expense $286.0K $543.0K $210.0K
YoY Change -47.33% 454.08% -28.81%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$31.23M -$9.153M -$6.168M
YoY Change 241.18% -5.64% -29.18%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$31.23M -$9.153M -$6.168M
YoY Change 241.18% -5.59% -29.22%
Net Earnings / Revenue -451.92% -168.04% -87.99%
Basic Earnings Per Share
Diluted Earnings Per Share -$682.9K -$248.5K -$167.9K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.00M $72.32M $83.58M
YoY Change 25.82% 73.86% 69.52%
Cash & Equivalents $27.65M $16.80M $37.86M
Short-Term Investments $63.40M $55.53M $45.72M
Other Short-Term Assets $8.000M $98.00K $5.085M
YoY Change 8063.27% -94.84% 3431.25%
Inventory
Prepaid Expenses $2.258M
Receivables $3.200M $0.00 $300.0K
Other Receivables $5.900M $5.200M $0.00
Total Short-Term Assets $108.1M $79.84M $91.00M
YoY Change 35.4% 80.63% 65.76%
LONG-TERM ASSETS
Property, Plant & Equipment $20.22M $9.151M $18.20M
YoY Change 121.0% 27.1% 323.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $4.800M $4.737M $4.783M
YoY Change 1.33% 238.36% 241.64%
Total Long-Term Assets $34.30M $51.31M -$86.82M
YoY Change -33.15% 45.76% -368.79%
TOTAL ASSETS
Total Short-Term Assets $108.1M $79.84M $91.00M
Total Long-Term Assets $34.30M $51.31M -$86.82M
Total Assets $142.4M $131.1M $4.180M
YoY Change 8.58% 65.17% -95.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.700M $2.577M $1.582M
YoY Change -34.03% 98.23% -45.45%
Accrued Expenses $14.13M $7.120M $6.900M
YoY Change 98.44% 14.84% 146.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change
Total Short-Term Liabilities $41.40M $25.69M $28.10M
YoY Change 61.13% 93.18% 132.23%
LONG-TERM LIABILITIES
Long-Term Debt $14.70M $3.075M $3.200M
YoY Change 378.05% -0.81% 6.7%
Other Long-Term Liabilities $1.427M $748.0K $374.0K
YoY Change 90.78% -16.89% -54.83%
Total Long-Term Liabilities $1.427M $3.823M $374.0K
YoY Change -62.67% -4.43% -90.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.40M $25.69M $28.10M
Total Long-Term Liabilities $1.427M $3.823M $374.0K
Total Liabilities $86.55M $41.89M $4.705M
YoY Change 106.63% 143.53% -71.13%
SHAREHOLDERS EQUITY
Retained Earnings -$217.4M -$110.0M
YoY Change 97.57%
Common Stock $273.1M $199.3M
YoY Change 37.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $55.86M $89.26M $96.14M
YoY Change
Total Liabilities & Shareholders Equity $142.4M $131.1M $140.6M
YoY Change 8.59% 65.17% 61.24%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$31.23M -$9.153M -$6.168M
YoY Change 241.18% -5.59% -29.22%
Depreciation, Depletion And Amortization $800.0K $500.0K $177.0K
YoY Change 60.0% 316.67% 145.83%
Cash From Operating Activities -$24.32M -$11.90M -$10.98M
YoY Change 104.37% 130.62% 22.19%
INVESTING ACTIVITIES
Capital Expenditures -$2.490M -$490.0K $625.0K
YoY Change 408.16% -80.16% -63.64%
Acquisitions
YoY Change
Other Investing Activities $10.16M -$9.470M -$35.30M
YoY Change -207.29%
Cash From Investing Activities $7.670M -$9.970M -$35.92M
YoY Change -176.93% 303.64% 1989.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$8.000K
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change -100.0%
Cash From Financing Activities 10.08M 810.0K 30.00K
YoY Change 1144.44% -8200.0% -97.19%
NET CHANGE
Cash From Operating Activities -24.32M -11.90M -10.98M
Cash From Investing Activities 7.670M -9.970M -35.92M
Cash From Financing Activities 10.08M 810.0K 30.00K
Net Change In Cash -6.570M -21.06M -46.87M
YoY Change -68.8% 175.65% 386.41%
FREE CASH FLOW
Cash From Operating Activities -$24.32M -$11.90M -$10.98M
Capital Expenditures -$2.490M -$490.0K $625.0K
Free Cash Flow -$21.83M -$11.41M -$11.60M
YoY Change 91.32% 324.16% 8.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsMember
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsMember
CY2020Q2 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentNet
CY2020Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2020Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
0
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
6909000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42473000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3429000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
55659000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45887000
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
8000
mtem Proceeds From Issuance Of Long Term Debt And Warrants Net
ProceedsFromIssuanceOfLongTermDebtAndWarrantsNet
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
221000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10893000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1029000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
2759000
mtem Increase Decrease In Grants Revenue Receivable
IncreaseDecreaseInGrantsRevenueReceivable
-1200000
mtem Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-122000
mtem Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
-2154000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
55859000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
89260000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
89260000
us-gaap Net Income Loss
NetIncomeLoss
-53246000
us-gaap Net Income Loss
NetIncomeLoss
-15321000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1318000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
301000
us-gaap Share Based Compensation
ShareBasedCompensation
5242000
us-gaap Share Based Compensation
ShareBasedCompensation
2803000
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
13000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87721000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30870000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19795000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16795000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3000000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19795000
us-gaap Interest Paid Net
InterestPaidNet
344000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
1600000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
839000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67926000
mtem Proceeds From Issuance Of Long Term Debt And Warrants Net
ProceedsFromIssuanceOfLongTermDebtAndWarrantsNet
14677000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5176000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
847000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30870000
us-gaap Interest Paid Net
InterestPaidNet
248000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
145000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
62000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
25000
mtem Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
11979000
mtem Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
0
mtem Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
-12676000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22878000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1121000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25277000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10169000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-57581000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88451000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27645000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3225000
CY2020Q2 mtem Other Liabilities Related Party Non Current
OtherLiabilitiesRelatedPartyNonCurrent
6654000
CY2019Q4 mtem Other Liabilities Related Party Non Current
OtherLiabilitiesRelatedPartyNonCurrent
0
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1427000
CY2020Q2 us-gaap Liabilities
Liabilities
86551000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1366000
CY2019Q4 us-gaap Liabilities
Liabilities
71174000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2020Q2 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45778876
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
18000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30414000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10243000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51045000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18697000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6412000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4605000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12059000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9540000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
36826000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
14848000
us-gaap Operating Expenses
OperatingExpenses
63104000
us-gaap Operating Expenses
OperatingExpenses
28237000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29917000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9401000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52054000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15782000
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
286000
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
543000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
758000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1053000
CY2020Q2 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
360000
CY2019Q2 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
301000
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
708000
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
594000
CY2020Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1237000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2019Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31228000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45778876
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45589157
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45589157
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
46000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
46000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
273012000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
267089000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
172000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217371000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-164125000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
55859000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
103028000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
142410000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
174202000
CY2019Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
5447000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
11050000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
12455000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
60171000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
38323000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9153000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53241000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15321000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-31228000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-9153000
us-gaap Net Income Loss
NetIncomeLoss
-53246000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31228000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9153000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53246000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15321000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45725481
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36819846
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45687278
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36779638
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31228000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9153000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53246000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15321000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-110000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
25000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
154000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
25000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31338000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9128000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53092000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15296000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
83766000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
96137000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
103028000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
100906000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
55859000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
243000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
14000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-240000
mtem Increase Decrease In Grants Revenue Receivable
IncreaseDecreaseInGrantsRevenueReceivable
0
mtem Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
678000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4443000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2020Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
63361000
CY2020Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2020Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
87865000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
125505000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
39633000
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1510000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
125505000
mtem Noncash Right Of Use Asset Obtained In Exchange For Operating Lease Obligations
NoncashRightOfUseAssetObtainedInExchangeForOperatingLeaseObligations
7295000
mtem Noncash Adoption Of Accounting Standards Codification
NoncashAdoptionOfAccountingStandardsCodification
0
mtem Noncash Adoption Of Accounting Standards Codification
NoncashAdoptionOfAccountingStandardsCodification
4179000
mtem Noncash Investing And Financing Activities
NoncashInvestingAndFinancingActivities
145000
mtem Noncash Investing And Financing Activities
NoncashInvestingAndFinancingActivities
13074000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
681000
mtem Noncash Right Of Use Asset Obtained In Exchange For Operating Lease Obligations
NoncashRightOfUseAssetObtainedInExchangeForOperatingLeaseObligations
0
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts in the prior year’s presentation have been reclassified to conform to the current presentation. The condensed consolidated balance sheet at December 31, 2019 included herein was derived from the audited financial statements at that date, but includes a reclassification of $8.8 million from Deferred revenue, current to Deferred revenue, current, related party and $0.4 million from Deferred revenue, non-current to Deferred revenue, non-current, related party in order to conform to current period presentation.  The condensed consolidated statements of cash flow for the six months ended June 30, 2019 included herein includes a reclassification of $12.7 million from Deferred revenue to Deferred revenue, related party. </p>
CY2019Q4 mtem Deferred Revenue Related Parties Current
DeferredRevenueRelatedPartiesCurrent
8800000
CY2019Q4 mtem Deferred Revenue Related Parties Noncurrent
DeferredRevenueRelatedPartiesNoncurrent
400000
mtem Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
-12700000
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
91000000.0
CY2020Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
0
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
0
CY2020Q2 mtem Finance Lease Expense
FinanceLeaseExpense
2000
mtem Finance Lease Expense
FinanceLeaseExpense
4000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s cash and cash equivalents are with two major financial institutions in the United States. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an ongoing credit evaluation of its strategic partners’ financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company’s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”) and <span style="Background-color:#FFFFFF;color:#000000;">Vertex Pharmaceuticals Incorporated (“Vertex”)</span>.  Takeda accounted for approximately 44% and 96% of total revenues for the three months ended June 30, 2020 and 2019 respectively and approximately 31% and 93% of the total revenues for the six months ended June 30, 2020 and June 30, 2019, respectively.  Vertex accounted for approximately $43% and 0% of total revenues for the three months ended June 30, 2020 and 2019, respectively and approximately 40% and 0% for the six months ended June 30, 2020 and June 30, 2019 respectively.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <span style="color:#000000;">July 2020, the Company became aware of one potentially non-conforming batch of a single Company product fill which may not meet manufacturing specifications. If upon the conclusion of the batch evaluation such batch is deemed to be non-conforming this could result in a reversal of revenue in future periods as the Company recognizes collaboration revenue over time by measuring </span>progress<span style="color:#000000;"> toward completion to satisfy the performance obligation. The Company does not believe this potential non-conforming batch will result in an increased timeline for its ongoing projects nor does it affect any other batches, production, or manufacturing.  The Company expects to be able to meet the supply needs for all of its active clinical trials. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug or biologic candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s drug or biologic candidates will receive any of the required approvals or clearances. If the Company were to be denied approval or clearance or any such approval or clearance were to be delayed, it would have a material adverse impact on the Company.</p>
CY2020Q2 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
6040000
CY2019Q2 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
5211000
mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
7840000
mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
11624000
CY2020Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
87865000
CY2019Q4 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
5774000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2860000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2849000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
45000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14129000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14544000
CY2019Q4 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
1383000
CY2020Q2 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
8041000
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
87693000
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
87865000
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
87693000
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
87865000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
123977000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
123995000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
1510000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1510000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
125487000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
125505000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1300000
CY2020Q2 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
1514000
CY2019Q4 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
4521000
CY2020Q2 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
1669000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21451000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3293000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20224000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18158000
CY2020Q2 us-gaap Depreciation
Depreciation
800000
CY2019Q2 us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
1500000
us-gaap Depreciation
Depreciation
800000
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
14700000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
3700000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
561000
us-gaap Operating Lease Cost
OperatingLeaseCost
1123000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
130000
us-gaap Variable Lease Cost
VariableLeaseCost
246000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
691000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1369000
CY2020Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
73359
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6629490
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.03
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
33600000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2306319
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.36
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9266000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1779000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10771000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12550000
CY2020Q2 mtem Finance Lease Right Of Use Asset Gross
FinanceLeaseRightOfUseAssetGross
77000
CY2020Q2 mtem Finance Lease Right Of Use Asset Accumulated Depreciation
FinanceLeaseRightOfUseAssetAccumulatedDepreciation
45000
CY2020Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
32000
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0671
CY2020Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0651
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1272000
CY2020Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
6000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2589000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2650000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1961000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1474000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1517000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4243000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15706000
CY2020Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
6000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3156000
CY2020Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
0
CY2020Q2 mtem Lessee Operating Lease Liability Total Lease Payments Net Of Interest
LesseeOperatingLeaseLiabilityTotalLeasePaymentsNetOfInterest
12550000
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
6000
us-gaap Operating Lease Payments
OperatingLeasePayments
1245000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
13000
CY2020Q2 mtem Upfront Fees Unamortized Balance Included In Prepaid Asset
UpfrontFeesUnamortizedBalanceIncludedInPrepaidAsset
1000000.0
CY2020Q2 us-gaap Contractual Obligation
ContractualObligation
13500000
mtem Development Costs Sharing Percentage Exercised
DevelopmentCostsSharingPercentageExercised
0.50
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3050000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1442000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
35100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M6D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4763062
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.36
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
36600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2129506
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.58
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
189719
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.59
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
17400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000000.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
700000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
800000
mtem Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options1
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions1
0
mtem Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options1
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions1
0
CY2019 mtem Impairment Of Long Lived Assets Held For Sale
ImpairmentOfLongLivedAssetsHeldForSale
22100000
CY2019Q4 mtem In Process Research And Development Held For Sale Current
InProcessResearchAndDevelopmentHeldForSaleCurrent
4500000

Files In Submission

Name View Source Status
0001564590-20-038063-index-headers.html Edgar Link pending
0001564590-20-038063-index.html Edgar Link pending
0001564590-20-038063.txt Edgar Link pending
0001564590-20-038063-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mtem-10q_20200630.htm Edgar Link pending
mtem-10q_20200630_htm.xml Edgar Link completed
mtem-20200630.xsd Edgar Link pending
mtem-20200630_cal.xml Edgar Link unprocessable
mtem-20200630_def.xml Edgar Link unprocessable
mtem-20200630_lab.xml Edgar Link unprocessable
mtem-20200630_pre.xml Edgar Link unprocessable
mtem-ex103_362.htm Edgar Link pending
mtem-ex311_7.htm Edgar Link pending
mtem-ex312_6.htm Edgar Link pending
mtem-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending